USPTO serial 97016583
INVICRO A KONICA MINOLTA COMPANY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- JOHNSON, DANYTHE ELIZABETH HA
- Law office
- TMO LAW OFFICE 120 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with INVICRO A KONICA MINOLTA COMPANY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Carrie L. Kiedrowski
Carrie L. Kiedrowski Jones Day250 VESEY STREETNEW YORK, NY 10281-1047UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer software for processing, visualizing, storing and analyzing pre-clinical and clinical radiology and pathology image data in the fields of drug development and disease research; downloadable computer software for image data management purposes, namely, pre-clinical and clinical image database management and research subject records management; downloadable computer software for processing multi-modal imaging data; downloadable computer software for the processing, storage and analysis of multi-modal imaging data for quantitation and evaluation of biomarkers and drug candidates; downloadable software for the assessment of tumors for research through use of biomarkers | ACTIVE | Mar 1, 2018 |
| 041 | Educational services, namely, developing, arranging and conducting educational programs, panel discussions and webinars in the fields of pharmaceuticals, biotechnology, pre-clinical and clinical trials, and medical research; educational services, namely, providing non-downloadable publications, and literature in the fields of pharmaceuticals, biotechnology, pre-clinical and clinical trials, and medical research | ACTIVE | Mar 1, 2018 |
| 042 | Medical and scientific research, namely, conducting clinical and pre-clinical trial services for others; pharmaceutical research and development services; testing of pharmaceutical pharmacodynamics, pharmacokinetics and efficacy using a variety of imaging modalities and imaging analysis platforms; imaging services and pathology in support of pharmaceutical research and development; drug discovery services; conducting early evaluations in the field of new drugs; scientific investigations for medical research purposes; medical and scientific research laboratory services; medical and scientific research, namely, providing analysis of imaging data obtained from pre-clinical and clinical trial studies; medical and scientific research in the fields of medical radiology imaging, pathology and digital pathology; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; research and development in the fields of medical imaging, pharmaceuticals and biotechnology; design, development, maintenance and updating of computer software for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; electronic storage of medical images; processing and analysis of medical images; pathology services in support of drug development; hosting of a medical imaging analysis and visualization platform through a global computer network; hosting of a database of medical images; software as a service (SAAS) featuring computer software platforms for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; conducting clinical trials for others at all stages and in various indications, particularly in oncology, neurology and systemic diseases; imaging contract research organization services and technology solutions, namely, imaging services for medical and scientific research purposes and technology solutions, namely, reviewing of radiology images throughout the clinical trial process and blinded independent central review of radiology images in the medical research and clinical trial setting; scientific research services, namely, integration of imaging results with clinical outcome data, with application of machine learning and artificial intelligence applications; development and evaluation of imaging biomarkers for clinical trial purposes; software consulting services in the field of drug discovery; cloud computing featuring software for use in pharmaceutical drug research in the field of drug discovery; radiochemistry services; research, development and testing services relating to radiopharmaceuticals; radiolabeling scientific research, namely, labeling of both small molecules and biologics; providing non-downloadable web-based computer software for database management in the fields of medical imaging, pharmaceutical and biotechnology research | ACTIVE | Mar 1, 2018 |
| 044 | Medical imaging services; medical imaging and radiology services related to drug development; research services in the fields of magnetic resonance and molecular imaging; medical research services, in particular services relating to the development of radiotherapeutics and drug candidates for neurodegenerative diseases and precision oncology; image analysis and radiology, namely, analysis of images from all radiological modalities, such as but not limited to CT, MRI and PET scans to provide quantitative evaluation of drug candidates medical radiology, namely, molecular imaging, imaging utilizing radiopharmaceuticals; radiomics, namely, medical radiology services; medical imaging services, namely, medical imaging and extraction of imaging biomarkers; pathology services, namely, testing for research purposes in the fields of pharmaceuticals and biotechnology; pathology services for preclinical biomarker discovery research and clinical trials | ACTIVE | Mar 1, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Invicro, LLC
- Other trademarks in Class 009
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named INVICRO A KONICA MINOLTA COMPANY
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 19, 2023 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 19, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 19, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 6, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 6, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 6, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 6, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 6, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 7, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 19, 2021 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 18, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 11, 2021 | NWAP | NEW APPLICATION ENTERED | — |